I'm glad to see an Amarex rep will present tomorrow... hopefully he/she will address the many questions about how the trial process works... why it's so difficult for example to get Covid-19 patients on board, whether criteria is requested by CytoDyn, Amarex, the FDA or any other person/entity involved or more than any one of them. I'd also like to hear more specific timelines and budgets for these trials, and what could happen along the way to change original specifications/process.

If these matters are not part of the presentation by the Amarex rep, it would be great for a caller to ask about them so we can get a clear and fuller picture.

Also, maybe Dr. Pourhassan (since Dr. Patterson is unavailable) will have a good new update on the peer review of the study submission... and of course anything about potential funding... whether from a Fed agency, investment firm or other... Dr. Lalezari may also have something on that and of course tell us about how the Triple-Negative Breast Cancer enrollment is going...

Speaking of that trial, I told a friend who's sister is dealing with stage four about Leronlimab just yesterday and she wanted the trial info to contact Dr. Lalezari... maybe he'll tell the number of interested patients has grown to more than the 10 he recently mentioned.